1851. Deputy Paul Murphy asked the Minister for Health if his attention has been drawn to the fact that in September 2020 the National Centre for Pharmacoeconomics refused reimbursement for the life-changing gene therapy luxturna unless cost effectiveness can be improved relative to existing treatments; if his attention has been further drawn to the fact that there are no existing treatments for inherited retinal disease (details supplied); if he will request that the National Centre for Pharmacoeconomics review its decision and include the drug in the list of drug treatments approved for reimbursement; and if he will make a statement on the matter. [19135/21]

Summary

1851. Deputy Paul Murphy asked the Minister for Health if his attention has been drawn to the fact that in September 2020 the National Centre for Pharmacoeconomics refused reimbursement for the life-changing gene therapy luxturna unless cost effectiveness can be improved relative to existing treatments; if his attention has been further drawn to the fact that there are no existing treatments for inherited retinal disease (details supplied); if he will request that the National Centre for Pharmacoeconomics review its decision and include the drug in the list of drug treatments approved for reimbursement; and if he will make a statement on the matter. [19135/21]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 21 April 2021

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.